MadanJagasiaMD

Oncology • Nashville, TN

Associate Professor, Medicine, Vanderbilt University School of Medicine

Join to view full profile

Dr. Jagasia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jagasia's full profile

Already have an account?

Office
3601 21st Ave S
Nashville, TN 37232
Phone+1 615-322-3000

Fax+1 615-936-0605

Summary

Dr. Madan Jagasia is an oncologist in Nashville, TN and is affiliated with multiple hospitals in the area, including Vanderbilt University Medical Center and Tennessee Valley Healthcare System. He received his medical degree from Seth G.S. Medical College and has been in practice 28 years. He also speaks multiple languages, including Hindi. He specializes in hematologic oncology and is experienced in hematologic oncology and stem cell transplantation, with a research focus on Graft-versus-host disease

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
Methodist Le Bonheur Healthcare/CentralResidency, Internal Medicine, 1994 - 1996
Nassau University Medical CenterInternship, Internal Medicine, 1993 - 1994
Seth G.S. Medical CollegeClass of 1989

Certifications & Licensure

TN State Medical License 1997 - 2025
AL State Medical License 2020 - 2020
AR State Medical License 1995 - 2001
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Completed
Phase 2
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Start of enrollment: 2008 Oct 01
Completed
Phase 3
Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant Start of enrollment: 2007 Jan 01
Completed
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant Start of enrollment: 2008 Nov 01
Terminated
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Start of enrollment: 2010 Nov 01
Completed
Phase 2
Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis Start of enrollment: 2011 Jul 01
Terminated
Not Applicable
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Start of enrollment: 2011 Nov 01
Completed
Phase 2
Brentuximab Vedotin for Steroid Refractory GvHD Start of enrollment: 2012 Jul 01
Completed
Phase 1
Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE) Start of enrollment: 2014 Aug 29
Terminated
Tocilizumab for Chronic Graft-versus-Host Disease Treatment Start of enrollment: 2016 Feb 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

113 citations
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
Robert F. Cornell, Bonnie Ky, Brendan M. Weiss, Cherie N. Dahm, Deepak K. Gupta
Journal of Clinical Oncology. 2019-06-12
271 citations
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Tri...
Kenneth R. Cooke, Leo Luznik, Stefanie Sarantopoulos, Frances T. Hakim, Madan Jagasia
Biology of Blood and Marrow Transplantation. 2017-02-01
486 citations
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Madan Jagasia, Mukta Arora, Mary E.D. Flowers, Nelson J. Chao, Philip L. McCarthy
Blood. 2012-01-05

Lectures

Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

$Ruxolitinib Improves Outcomes in Patients with Steroid-Refractory Graft-Versus-Host Disease$
Ruxolitinib Improves Outcomes in Patients with Steroid-Refractory Graft-Versus-Host DiseaseJune 1st, 2020
MaaT Pharma Announces Formation of Its GvHD-Focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-Oncological IndicationsMay 12th, 2020
Longer Looks: Public Housing, Small Pox Experts, Climate Change in the Time of Coronavirus, and MoreMarch 27th, 2020
Join now to see all